The American Roentgen Ray Society (ARRS) will convene its 2021 Annual Meeting as an all-virtual event from April 18-22, 2021. The first imaging society to announce an all-virtual assembly for 2021, ARRS promises to deliver the same clinically relevant experience for which its Annual Meeting has long been heralded: world-class educational activities led by the field’s foremost experts that span…

Researchers at the University of Bern have discovered a mechanism in the body’s own immune system which is responsible for the maturation and activation of immune cells. In the fight against skin cancer, the results have the potential to help immunotherapies succeed, even in patients for whom they have so far been ineffective.

Drugs tackling chronic myelogenous leukemia have completely transformed prognoses of patients over the last couple of decades, with most cases going into remission. But drug resistance can occur, leading to relapses. Targeting the lipids involved in regulating part of a leukemia stem cell’s life span offers a potential second route to defeat the disease–and solid tumorous cancers as well.

Researh teams of Tokyo Medical and Dental University (TMDU) and Harvard Medical School (HMS) have uncovered how to increase the efficacy of anti-PD-L1 immunotherapy. Using a combination of molecular, biochemical, and bioinformatics approaches, they discovered that the nuclear localization of PD-L1 is controlled by acetylation at a single, specific, Lys site. In the nucleus, PD-L1 controls the…

The Centre for Probe Development and Commercialization (CPDC) and adMare BioInnovations (adMare) are pleased to announce they have formed a new collaboration, ”The CPDC-adMare Radiopharmaceutical Initiative (CARI)” to bring their respective resources together to advance an area of tremendous therapeutic and commercial potential in which Canada can gain a considerable global competitive…

An immunotherapy drug called ‘avelumab’ has been shown to significantly improve survival in patients with the most common type of bladder cancer, according to results from a phase III clinical trial led by Queen Mary University of London and Barts Cancer Centre, UK.

Access to cancer medicines is highly unequal across Europe both for new drugs in development because of uneven access to clinical trials and for currently approved drugs due to huge disparities in healthcare spending by different countries, according to results from studies presented at ESMO 2020.

Researchers studying the activity of gut bacteria in breast cancer patients have found a possible link with how well their chemotherapy works.

Breast cancer patients whose disease has spread to their brains fare better if their metastases are picked up before they begin to cause symptoms, according to a study presented at the 12th European Breast Cancer Conference.